ApaTech attracts seasoned spinal executive as VP OUS markets
This article was originally published in Clinica
Executive Summary
ApaTech (Hertfordshire, UK), a specialist in the production of synthetic bone repair material and bone graft technologies, has appointed Geert Hertecant as vice-president for all markets outside the US. The company currently supplies to 21 countries, with leading markets being the UK and Germany. Mr Hertecant joins from Medtronic, where he was regional business director for North Europe of the spine and biologics division. He is a seasoned Medtronic executive: having joined the company as business manager for the spine division, he later joined Kyphon (minimally-invasive spinal function restoration therapies) as regional business director for North Europe; when Kyphon was bought by Medtronic in 2007, Mr Hertecant continued to serve in the role at Medtronic. “Geert brings a strong track record of successfully launching new products across Europe,” said Simon Cartmell, CEO of ApaTech.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.